Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.
Follow-Up Questions
Who is the CEO of Better Therapeutics Inc?
Mr. Craig Jalbert is the President of Better Therapeutics Inc, joining the firm since 2024.
What is the price performance of BTTX stock?
The current price of BTTX is $0.0002, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Better Therapeutics Inc?
Better Therapeutics Inc belongs to Health Care industry and the sector is Health Care
What is Better Therapeutics Inc market cap?
Better Therapeutics Inc's current market cap is $9972
Is Better Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Better Therapeutics Inc, including 2 strong buy, 5 buy, 1 hold, 0 sell, and 2 strong sell
